×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Bladder Cancer
Arjun V. Balar, M.D.
An expert discusses the future of immunotherapy in light of new frontline treatments like Keytruda that have been demonstrating positive results for patients with non–muscle invasive bladder cancer.
Jessica Skarzynski
Women with frequent urinary tract infections (UTIs) were more likely to experience lower quality diagnostic processes when it comes to screening for bladder and kidney cancer.
Katie Kosko
Although muscle-invasive disease is often treated by removal of the bladder, experts reveal potential high risk of death.
Kristie L. Kahl
At the 2019 Genitourinary Cancers Symposium, Arjun V. Balar discussed the past, present and future of immunotherapy for the treatment of bladder cancer.
Katie Kosko
After a review of more than 600,000 people, researchers discovered an association between foods consumed and bladder cancer risk.
Katie Kosko
Using tumor DNA found in urine, researchers believe they have found a method to diagnose and monitor bladder cancer that outperforms standard tests.
Kristie L. Kahl
After patients with non–muscle invasive bladder cancer fail to respond to treatment with BCG immunotherapy, Keytruda (pembrolizumab) may induce responses in these high-risk patients.
Kristie L. Kahl
Vofatamab (B-701) may be safe and effective for patients with locally advanced or metastatic bladder cancer with an FGFR3 mutation who have relapsed after, or are refractory to, at least one prior line of chemotherapy, according to preliminary findings.
Kristie L. Kahl
An integrative model helped to determine which patients with bladder cancer may benefit from checkpoint inhibitor therapy.
Katie Kosko
Although chemotherapy and radical cystectomy are traditionally used to treat muscle-invasive disease, a recent analysis shows similar overall survival outcomes in patients treated with chemoradiotherapy.